Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03477175 · ClinicalTrials.gov registry record · Phase 2
Study to Assess the Long-term Safety of Lenvatinib Monotherapy, a Lenvatinib Combination Regimen, or a Comparator Treatment Arm to Cancer Participants in Eisai Sponsored Lenvatinib Trials
A Phase 2 study, sponsored by Eisai.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT03477175 is a Phase 2 study that has completed, run by Eisai. The registered enrollment target is 40 participants.
The verdict
NCT03477175, a Phase 2 study, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
This study will be conducted to assess the long-term safety of study drug(s) in participants who are enrolled in Eisai-sponsored lenvatinib studies.
Interventions
- DRUG E7080
- DRUG Comparator Drug
- DRUG Comparator Drug: Sorafenib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2018-08-16 |
| Est. Completion | 2023-12-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03477175
The ClinicalTrials.gov registry entry for NCT03477175 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which E7080 is the first listed.
NCT03477175 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03477175 about?
NCT03477175 is a clinical study titled "Study to Assess the Long-term Safety of Lenvatinib Monotherapy, a Lenvatinib Combination Regimen, or a Comparator Treatment Arm to Cancer Participants in Eisai Sponsored Lenvatinib Trials". This study will be conducted to assess the long-term safety of study drug(s) in participants who are enrolled in Eisai-sponsored lenvatinib studies.
What is the current status of trial NCT03477175?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2018-08-16. Estimated completion is 2023-12-21.
What interventions are being tested in trial NCT03477175?
The interventions under investigation include: E7080 (DRUG), Comparator Drug (DRUG), Comparator Drug: Sorafenib (DRUG).
Who is sponsoring clinical trial NCT03477175?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.